European Hematology Association

Geron to Host Virtual Investor Event on June 14, 2023

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Ruxolitinib, Clinic, European Hematology Association, Hematology, Cell therapy, American Society of Clinical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Teaching hospital, Acute myeloid leukemia, ASCO, MDS, Imetelstat, Corporation, Geron Corporation, Risk, EHA, Annual general meeting, Webcast, Society, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time.
  • Topics to be covered at the event include:
    Summary of new IMerge Phase 3 data in lower risk myelodysplastic syndromes (MDS) featured in 2023 medical meetings.
  • This includes presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023 and upcoming presentations at the European Hematology Association (EHA) Annual Meeting taking place from June 8-11, 2023.
  • An archive of the webcast will be available on the Company’s website for 30 days.

Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Friday, June 9, 2023
Civil service commission, European Hematology Association, Associate professor, New Drug Application, Survival, Drug, Trae tha Truth, Mutation, Hyponatremia, Acute myeloid leukemia, MD Anderson Cancer Center, Tablet, MDS, MSCE, Breakthrough therapy, Congress, Induction chemotherapy, AML, Azacitidine, Shanda, HIV disease progression rates, Patient, Division, Syndrome, University, EHA, IDH, CR, IDH1, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ORR, Food, European Commission, Safety, Fatigue, Pharmaceutical industry

BOSTON, June 9, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced updated data from the Phase 1 trial of TIBSOVO® (ivosidenib tablets) as monotherapy for patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). The results presented today at the European Hematology Association (EHA) 2023 Annual Congress in Frankfurt, Germany demonstrate that the efficacy and safety profile of TIBSOVO may provide an important new treatment option for MDS patients within this molecularly defined subset.

Key Points: 
  • The results presented today at the European Hematology Association (EHA) 2023 Annual Congress in Frankfurt, Germany demonstrate that the efficacy and safety profile of TIBSOVO may provide an important new treatment option for MDS patients within this molecularly defined subset.
  • The Phase 1, open-label study included an evaluation of the safety, tolerability, and clinical activity of TIBSOVO in patients with IDH1-mutated R/R MDS.
  • In the efficacy analysis set (n=18), a complete remission (CR) rate of 38.9% and overall response rate (ORR) of 83.3% were documented in patients treated with TIBSOVO.
  • Servier plans to submit a supplemental New Drug Application (sNDA) based on these results to the U.S. FDA for TIBSOVO in adult patients with R/R IDH1-mutated myelodysplastic syndromes.

AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients

Retrieved on: 
Friday, June 9, 2023
CLL, Neutropenia, Rituximab, Obinutuzumab, Febrile neutropenia, Ars, Royal Melbourne Hospital, European Hematology Association, Diarrhea, German, Grade 3, ABBV, Roche, Aes, Bone marrow, OS, Cytokine, PFS, MRD, Congress, Chlorambucil, AbbVie, Patient, Anemia, Confidence interval, EHA, Hematology, Nausea, Press, Upper respiratory tract infection, Safety, Thrombocytopenia, NYSE, Venetoclax, Pneumonia, Fatigue, Pharmaceutical industry, Fine chemical, Genentech

The results are being presented during oral sessions at the European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.

Key Points: 
  • The results are being presented during oral sessions at the European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.
  • "These results underscore our commitment to transform how blood cancers are treated today and show that venetoclax can give patients lasting results with time off treatment."
  • New six-year follow-up results from the Phase 3 CLL14 study showcase updated outcomes in previously untreated patients with CLL and co-existing conditions.
  • "These results confirm the treatment benefits of fixed-duration venetoclax and obinutuzumab for previously untreated CLL patients with co-existing conditions."

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Saturday, June 3, 2023
Research and development, CD19, European Hematology Association, American Society of Clinical Oncology, Cancer, Cyclophosphamide, Month, Leukapheresis, B-cell lymphoma, ASCO, CAR, Development, Kite Pharma, HIV disease progression rates, Patient, SAN, EHA, Annual general meeting, CR, CRS, Therapy, Society, Pharmaceutical industry

These data will also be presented in a poster session at the European Hematology Association (EHA) Hybrid Congress on June 9, 2023.

Key Points: 
  • These data will also be presented in a poster session at the European Hematology Association (EHA) Hybrid Congress on June 9, 2023.
  • As of the data cutoff, 7 of 12 (58%) patients achieved a CR and five (42%) maintained a CR through Month 6.
  • Of the five patients who were in CR at 6 months, four (80%) remained in CR.
  • The median duration of response was 23.1 months with three patients remaining in remission for over 24 months and the longest remaining in remission for over 31 months.

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Retrieved on: 
Friday, June 2, 2023
Therapy, European Hematology Association, Genetics, ALL, DLBCL, Multiple myeloma, NGS, American Society of Clinical Oncology, Clinical trial, PFS, B-cell lymphoma, ASCO, MRD, Acute leukemia, Hematological Cancer Research Investment and Education Act, Patient, Physician, Data, Flow cytometry, Annual general meeting, EHA, ADPT, MM, Poster, Neoplasm, MASTER, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Medical imaging

SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical significance of minimal residual disease (MRD) assessment at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, as well as the European Hematology Association (EHA) Hybrid Congress taking place June 8-11 in Frankfurt, Germany. Data will be presented from clinical trials and real-world evidence studies using Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers.

Key Points: 
  • Data will be presented from clinical trials and real-world evidence studies using Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers.
  • “Adaptive has demonstrated the value of NGS-MRD assessment in hematologic cancers.
  • This assessment is performed as a series of tests in clinical trials and throughout a patient’s cancer journey.
  • Data continues to show the potential for MRD assessment to help in the personalization of cancer care.

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO

Retrieved on: 
Friday, June 2, 2023
Neutropenia, University College London, UCL, CD19, European Hematology Association, ALL, CRS, Safety, Toxicity, Doctor of Philosophy, Associate, Acute leukemia, ASCO, MRD, UCLH, CAR, American Society of Clinical Oncology, Patient, B-ALL, Nursing, Physician, Royal College of Pathologists, EHA, Annual general meeting, CRi, CR, Pivotal, Neoplasm, Therapy, Kinetics, Society, Thrombocytopenia, BST, Maintenance (technical), Vaccine, Pharmaceutical industry, MD

In the pivotal morphological cohort of the FELIX trial, 112 patients with r/r adult ALL were enrolled and 94 (84%) patients were dosed with obe-cel.

Key Points: 
  • In the pivotal morphological cohort of the FELIX trial, 112 patients with r/r adult ALL were enrolled and 94 (84%) patients were dosed with obe-cel.
  • Furthermore, at a 9.5-month median follow up, 61% of responders remained in ongoing remission without new anti-cancer therapies.
  • CAR T cellular kinetics demonstrate excellent CAR T engraftment and persistence and are consistent with the prior ALLCAR19 study.
  • Obe-cel shows low immunotoxicity, high complete remission rates and excellent CAR T expansion and persistence in adult B-ALL.

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, European Hematology Association, Paroxysmal nocturnal hemoglobinuria, Consultant, Pharmacokinetics, Society for Integrative Oncology, Haematopoietic system, Teaching hospital, Congress, Corporation, MD, Royal College of Pathologists, CEST, PNH, EHA, Patient, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Identified as one of the top five late-breaking submissions by the Scientific Program Committee, the abstract was selected for oral presentation.

Key Points: 
  • Identified as one of the top five late-breaking submissions by the Scientific Program Committee, the abstract was selected for oral presentation.
  • The presentation abstract (#LB2714) was embargoed by EHA until 16:00 CEST today but now is freely accessible on EHA’s website.
  • Following Dr. Panse’s presentation, Omeros will make available on its website the associated slides.
  • Dr. Griffin’s presentation is scheduled for 18:00-19:00 CEST on Friday, June 9, 2023 and will be available for viewing by registered attendees on the online EHA platform throughout the duration of the congress (June 8-11, 2023).

iOnctura to present research at leading scientific conferences in June 2023

Retrieved on: 
Thursday, June 1, 2023
European Hematology Association, Research, ASCO, Congress, Patrick Schöffski, American Society of Clinical Oncology, CEST, EHA, Annual general meeting, Society, Pharmaceutical industry

GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.

Key Points: 
  • GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.
  • The iOnctura team will present the Company's research on its first-in-class, non-ATP-competitive, allosteric modulator of PI3Kδ, roginolisib.
  • American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA
    European Hematology Association (EHA) Hybrid Congress, Frankfurt, Germany
    European Association for Cancer Research (EACR) Congress 2023, Torino, Italy
    Presentation Time: 14 June 2023 at 11:00-18:00 CEST.

iOnctura to present research at leading scientific conferences in June 2023

Retrieved on: 
Thursday, June 1, 2023
European Hematology Association, Research, ASCO, Congress, Patrick Schöffski, American Society of Clinical Oncology, CEST, EHA, Annual general meeting, Society, Pharmaceutical industry

GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.

Key Points: 
  • GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.
  • The iOnctura team will present the Company's research on its first-in-class, non-ATP-competitive, allosteric modulator of PI3Kδ, roginolisib.
  • American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA
    European Hematology Association (EHA) Hybrid Congress, Frankfurt, Germany
    European Association for Cancer Research (EACR) Congress 2023, Torino, Italy
    Presentation Time: 14 June 2023 at 11:00-18:00 CEST.

Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023

Retrieved on: 
Wednesday, May 31, 2023
European Hematology Association, SYK, TUS, Cell, Acute myeloid leukemia, KIT, Drug resistance, AML, Patient, SAN, EHA, FLT3, TSX, International Congress on Tuberculosis, Phenotype, Venetoclax, Safety, Pharmaceutical industry, Vaccine

The webcast event will include an interim review of Aptose’s lead compound tuspetinib, a myeloid kinase inhibitor, currently being tested as a monotherapy and in combination with venetoclax in the phase 1/2 APTIVATE trial.

Key Points: 
  • The webcast event will include an interim review of Aptose’s lead compound tuspetinib, a myeloid kinase inhibitor, currently being tested as a monotherapy and in combination with venetoclax in the phase 1/2 APTIVATE trial.
  • Aptose management will highlight additional insights from the completed Phase 1/2 dose escalation clinical trial of tuspetinib and review early trends from the ongoing APTIVATE trial.
  • The slides will be available on Aptose’s website here and the webcast of the presentation will be archived shortly after the conclusion of the event.
  • Strikingly, acquired TUS resistance generated a synthetic lethal vulnerability in which the cells were unusually hypersensitive to venetoclax.